Hong Kong · Delayed Price · Currency is HKD RemeGen Statistics
Total Valuation
RemeGen has a market cap or net worth of HKD 75.51 billion. The enterprise value is 75.27 billion.
| Market Cap | 75.51B |
| Enterprise Value | 75.27B |
Important Dates
The next confirmed earnings date is Tuesday, April 28, 2026.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RemeGen has 559.97 million shares outstanding. The number of shares has increased by 2.28% in one year.
| Current Share Class | 204.27M |
| Shares Outstanding | 559.97M |
| Shares Change (YoY) | +2.28% |
| Shares Change (QoQ) | +2.22% |
| Owned by Insiders (%) | 11.87% |
| Owned by Institutions (%) | 29.34% |
| Float | 344.63M |
Valuation Ratios
The trailing PE ratio is 72.59 and the forward PE ratio is 14.51.
| PE Ratio | 72.59 |
| Forward PE | 14.51 |
| PS Ratio | 20.87 |
| PB Ratio | 18.80 |
| P/TBV Ratio | 19.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 1,281.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 150.52, with an EV/FCF ratio of -459.95.
| EV / Earnings | 95.31 |
| EV / Sales | 20.81 |
| EV / EBITDA | 150.52 |
| EV / EBIT | n/a |
| EV / FCF | -459.95 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.43 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 4.90 |
| Debt / FCF | -14.97 |
| Interest Coverage | 1.99 |
Financial Efficiency
Return on equity (ROE) is 25.37% and return on invested capital (ROIC) is 4.16%.
| Return on Equity (ROE) | 25.37% |
| Return on Assets (ROA) | 1.37% |
| Return on Invested Capital (ROIC) | 4.16% |
| Return on Capital Employed (ROCE) | 3.14% |
| Weighted Average Cost of Capital (WACC) | 6.81% |
| Revenue Per Employee | 1.19M |
| Profits Per Employee | 259,090 |
| Employee Count | 3,048 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 0.63 |
Taxes
In the past 12 months, RemeGen has paid 833,151 in taxes.
| Income Tax | 833,151 |
| Effective Tax Rate | 0.11% |
Stock Price Statistics
The stock price has increased by +138.90% in the last 52 weeks. The beta is 0.49, so RemeGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +138.90% |
| 50-Day Moving Average | 93.86 |
| 200-Day Moving Average | 87.52 |
| Relative Strength Index (RSI) | 49.31 |
| Average Volume (20 Days) | 5,138,165 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RemeGen had revenue of HKD 3.62 billion and earned 789.71 million in profits. Earnings per share was 1.44.
| Revenue | 3.62B |
| Gross Profit | 3.16B |
| Operating Income | 155.64M |
| Pretax Income | 790.54M |
| Net Income | 789.71M |
| EBITDA | 436.16M |
| EBIT | 155.64M |
| Earnings Per Share (EPS) | 1.44 |
Balance Sheet
The company has 2.70 billion in cash and 2.45 billion in debt, with a net cash position of 245.62 million or 0.44 per share.
| Cash & Cash Equivalents | 2.70B |
| Total Debt | 2.45B |
| Net Cash | 245.62M |
| Net Cash Per Share | 0.44 |
| Equity (Book Value) | 4.02B |
| Book Value Per Share | 7.18 |
| Working Capital | 1.33B |
Cash Flow
In the last 12 months, operating cash flow was 58.93 million and capital expenditures -222.57 million, giving a free cash flow of -163.64 million.
| Operating Cash Flow | 58.93M |
| Capital Expenditures | -222.57M |
| Depreciation & Amortization | 288.93M |
| Net Borrowing | -170.04M |
| Free Cash Flow | -163.64M |
| FCF Per Share | -0.29 |
Margins
Gross margin is 87.22%, with operating and profit margins of 4.30% and 21.83%.
| Gross Margin | 87.22% |
| Operating Margin | 4.30% |
| Pretax Margin | 21.85% |
| Profit Margin | 21.83% |
| EBITDA Margin | 12.06% |
| EBIT Margin | 4.30% |
| FCF Margin | n/a |
Dividends & Yields
RemeGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 10.15% |
| Buyback Yield | -2.28% |
| Shareholder Yield | -2.28% |
| Earnings Yield | 1.05% |
| FCF Yield | -0.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RemeGen has an Altman Z-Score of 5.54 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.54 |
| Piotroski F-Score | 7 |